If you've started a GLP-1 medication and stopped, or you're worried you'd be wasting money by starting, here's something worth knowing: quitting is the norm, not the exception.
Those numbers surprise people, because the medications themselves work. In clinical trials, semaglutide and tirzepatide produced average weight reductions of roughly 15–20% over about 68–72 weeks, alongside diet and exercise changes. The science isn't the weak link.
So why do most people stop? When researchers dug into the data, two causes dominated: cost and unmanaged side effects. And here's the part almost nobody talks about — both of those are usually program problems, not medication problems. They're determined by which program you sign up with, often before your first dose ships.
1. The price shock that arrives at month two
Many programs advertise an attractive first-month price, then step up sharply — or the advertised price quietly excludes the consultation fee, the shipping, or the dose you'll actually need by month three. When the real monthly number lands, people quit. Not because they wanted to stop treatment, but because the math stopped working.
The range across legitimate, doctor-supervised programs is wider than most people expect:
Same class of medication. A difference of thousands of dollars a year. The people who stay on treatment overwhelmingly picked a program whose real, ongoing price fit their budget from day one — not the teaser price.
2. Side effects with nobody to call
Most GLP-1 side effects — nausea, digestive discomfort — are manageable with dose adjustments and clinical guidance, and they typically ease as your body adapts. But that requires a program where a licensed clinician actually responds when week three gets rough.
This is where programs differ enormously. Some offer weekly check-ins and care-team messaging through an app. Others are closer to a prescription vending machine: you get your shipment, and you're on your own. The data suggests that people in unsupported programs quietly quit when side effects appear — while people with responsive clinical support adjust the dose and continue.
3. The wrong medication, and no way to switch
Semaglutide and tirzepatide behave differently from person to person. Some people respond better to one than the other; some need a different dose curve than the standard schedule. Programs that lock you into a single medication leave you with two options when it isn't working: push through, or quit.
A smaller group of programs lets you switch medications under clinical supervision without starting over. In the retention data, that flexibility matters — it converts "this isn't working, I'm done" into "let's adjust."
What this actually means: it's a selection problem
Look at the three quit-drivers together. Sustainable price. Responsive clinical support. Medication flexibility. None of these depend on your willpower. All of them are locked in by the program you choose — usually in a ten-minute signup, usually without comparing alternatives.
That's the real takeaway from the 2026 retention data: the difference between the 65% who stop and the people still on track a year later often traces back to a decision made before the first dose ever shipped.
Find the program built for you to stay on it
Answer 5 questions about your budget, history, and goals. We compare all 24 LegitScript-certified, doctor-supervised programs we independently review and show you your best fit.
Find my match →One more honest note: no program makes GLP-1 effortless, and none of them removes the need for the diet and lifestyle changes the clinical results are built on. But if you're going to do the hard part anyway, it should be inside a program priced, supported, and flexible enough that you can actually finish what you start.
